This article is more than 5 years old. Information may no longer be current.
Retinal angiomatous proliferation patients may be treated with three consecutive loading doses of intravitreal ranibizumab
TORONTO — Three consecutive loading doses of intravitreal ranibizumab may be a treatment option for patients with retinal angiomatous proliferation, according to a poster presentation.
Patients with stage 1 retinal angiomatous proliferation had a lower number of treatments and, therefore, lower recurrence rates than those in stage 2 and stage 3, Young Gun Park, MD, and colleague, said in a poster presented at the American Society of Retina Specialists meeting.
Retrospective chart reviews of 41 eyes from 40 patients with a mean age of 67.09 were included in the study. Patients received three initial monthly intravitreal injections of ranibizumab; reinjection was administered on an as-needed basis with monthly monitoring for 12 months. The patients were measured for best corrected visual acuity and central macular thickness, along with the number of injections received in the 12 months.
“During the 12 months of follow-up following initial treatment, the mean number of treatments was significantly lower in stage 1 than stage 2 and 3 over 12 months after initial treatment,” the authors said.
Patients in stage 1 showed a significantly lower recurrence of retinal angiomatous proliferation than patients in stage 2 and stage 3, the study authors said.
Disclosure: The authors report no relevant financial disclosures.